

ILF COM: The Power of Social Media

RAMEWORK

Susie Murray, Professor Christine Moffatt, Susan Norregaard, Martina Sykorova

Why it matters?





To reach people who may otherwise not have a say especially patients and their families. The survey that was distributed via social media was completed by:

67.2% patients

Methods & Sampling strategy

TRENT UNIVERSITY

- **1.** Pilot survey
- **2.** Final survey on SurveyMonkey
- **3.** Social media campaign
- Official Lymphie Strong Inspiration Group





32.8% professionals

Who it matters to?

Patients

All patient groups, their families and carers

Professionals

Singapore

67.3%

Limb volume

International Lymphoedema Framework – Chronic Oedema Outcome Measure

All healthcare groups including medical device companies

Slovenia

Results

Reporting on 'Other country' option (484/8000): 47 participating countries in total:

Spain





Algeria	Angola	Argentina	Austria	Azerbaijan	Barbados	Bosnia and Hercegovina	Brazil
Bulgaria	Burkina Faso	Canary Islands	Chile	Costa Rica	Croatia	Cyprus	Dominican Republic
Egypt	Faroe Islands	Finland	Germany	Ghana	Greece	Honduras	India
Indonesia	Israel	Kenya	Lebanon	Luxembourg	Malaysia	Martinique	Montenegro
Morocco	Norway	Poland	Portugal	Qatar	Romania	Russia	Saudi Arabia



- Lymphedema
- Lymph-what-oedema



Official ILF account @ILF_Lympho



Tunisia

Official ILF website www.lympho.org





Respondents indicated that limb volume, quality of life status and mobility status are the most important chronic oedema/ in outcomes lymphoedema that should be measured (fig 1).

Figure 1: The most important outcome in

chronic oedema/lymphoedema that

should be measured (top 3)

59.7%


Quality of life status

Slovakia

2. Respondents indicated that the top 3 successful outcomes for chronic oedema/ lymphoedema are (fig 2): limb volume or oedema stable, quality of life is improved, and symptoms are controlled.

Sweden

3. The top 3 factors indicating that treatment is ineffective or failing were perceived as (fig 3): limb volume or oedema increased, symptoms are uncontrolled, and requirement for repeated intensive treatment.



Conclusions

Figure 3: What factors (top 3) indicate that treatment is ineffective or failing 70.0% 60.2% 60.0% 50.0% 50.0% 35.5% 40.0% 30.0% 20.0% 10.0%

0.0% Limb volume or oedema Symptoms uncontrolled Requirement for repeated increased intensive treatment



80.0% 70.0% 60.0% 50.0%

40.0%

30.0%

20.0%

10.0%



S Z 3

adoption of CO/ lymphoedema How

36.9%

Mobility status


Benefits of using social media within surveys:

• A new method for the ILF





Figure 4: Factors that could improve the adoption of CO outcome measures







🕥 🧭 🌍 🚾

- Possible to reach hard-to-reach groups
- Speed of survey circulation
- Easy to complete using a laptop or mobile phone

The ILF-COM survey was circulated on social media in December 2018 but the greatest number of responses was in March 2019.

